Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis

Monica Montepaone,1 Ennio Lubrano,2 Alessia Carboni,1 Antonio Spadaro1 1Unità Operativa Complessa di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, 2Academic Rheumatology Unit, Department of Medicine and Healt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Montepaone M, Lubrano E, Carboni A, Spadaro A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/1b8b03d81b5f4cfdb5d8f76afd8a797f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b8b03d81b5f4cfdb5d8f76afd8a797f
record_format	dspace
spelling	oai:doaj.org-article:1b8b03d81b5f4cfdb5d8f76afd8a797f2021-12-02T01:57:04ZProfile of ustekinumab and its potential in the treatment of active psoriatic arthritis1179-156Xhttps://doaj.org/article/1b8b03d81b5f4cfdb5d8f76afd8a797f2014-02-01T00:00:00Zhttp://www.dovepress.com/profile-of-ustekinumab-and-its-potential-in-the-treatment-of-active-ps-a15882https://doaj.org/toc/1179-156X Monica Montepaone,1 Ennio Lubrano,2 Alessia Carboni,1 Antonio Spadaro1 1Unità Operativa Complessa di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, 2Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy Abstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis and considered to be a less severe condition than rheumatoid arthritis. PsA patients have been treated for a long time with a number of different agents, from non-steroidal anti-inflammatory drugs to one or more disease-modifying antirheumatic drugs. In the last decade, recognition of the central role of tumor necrosis factor-alpha (TNFα) in the immunopathogenesis of many rheumatic diseases, including PsA, has led to the development of TNFα blockers. In PsA, these agents are uniquely efficacious in the treatment of different patterns of the disease, as well as slowing progression of erosive damage in the peripheral joints. However, a significant number of patients withdraw from therapy because of failure or poor tolerability. Among the novel therapeutic targets, interleukin (IL)-23/IL-12 has been investigated for the treatment of chronic inflammatory disease. In particular, ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells. Ustekinumab has been approved only for treatment of chronic plaque psoriasis, but also represents an interesting agent for treatment of PsA. Keywords: ustekinumab, psoriatic arthritis, psoriasis, interleukin-12, interleukin-23Montepaone MLubrano ECarboni ASpadaro ADove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2014, Iss default, Pp 7-13 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Montepaone M Lubrano E Carboni A Spadaro A Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
description	Monica Montepaone,1 Ennio Lubrano,2 Alessia Carboni,1 Antonio Spadaro1 1Unità Operativa Complessa di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, 2Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy Abstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis and considered to be a less severe condition than rheumatoid arthritis. PsA patients have been treated for a long time with a number of different agents, from non-steroidal anti-inflammatory drugs to one or more disease-modifying antirheumatic drugs. In the last decade, recognition of the central role of tumor necrosis factor-alpha (TNFα) in the immunopathogenesis of many rheumatic diseases, including PsA, has led to the development of TNFα blockers. In PsA, these agents are uniquely efficacious in the treatment of different patterns of the disease, as well as slowing progression of erosive damage in the peripheral joints. However, a significant number of patients withdraw from therapy because of failure or poor tolerability. Among the novel therapeutic targets, interleukin (IL)-23/IL-12 has been investigated for the treatment of chronic inflammatory disease. In particular, ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells. Ustekinumab has been approved only for treatment of chronic plaque psoriasis, but also represents an interesting agent for treatment of PsA. Keywords: ustekinumab, psoriatic arthritis, psoriasis, interleukin-12, interleukin-23
format	article
author	Montepaone M Lubrano E Carboni A Spadaro A
author_facet	Montepaone M Lubrano E Carboni A Spadaro A
author_sort	Montepaone M
title	Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
title_short	Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
title_full	Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
title_fullStr	Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
title_full_unstemmed	Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
title_sort	profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/1b8b03d81b5f4cfdb5d8f76afd8a797f
work_keys_str_mv	AT montepaonem profileofustekinumabanditspotentialinthetreatmentofactivepsoriaticarthritis AT lubranoe profileofustekinumabanditspotentialinthetreatmentofactivepsoriaticarthritis AT carbonia profileofustekinumabanditspotentialinthetreatmentofactivepsoriaticarthritis AT spadaroa profileofustekinumabanditspotentialinthetreatmentofactivepsoriaticarthritis
_version_	1718402759407960064

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis

Ejemplares similares